Literature DB >> 27920182

Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.

April M Clayton1.   

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for considerable epidemics worldwide and recently emerged in the Americas in 2013. CHIKV may cause long-lasting arthralgia after acute infection. With currently no licensed vaccines or antivirals, the design of effective therapies to prevent or treat CHIKV infection is of utmost importance and will be facilitated by increased understanding of the dynamics of chikungunya. In this article, monoclonal antibodies against CHIKV as viable prophylactic and therapeutic agents will be discussed.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  alphaviruses; chikungunya; monoclonal antibodies; therapies

Mesh：

Substances：

Year:  2016        PMID： 27920182      PMCID： PMC5853615          DOI： 10.1093/infdis/jiw324

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  32 in total

1.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

Review 2.  Chikungunya: Evolutionary history and recent epidemic spread.

Authors:  Scott C Weaver; Naomi L Forrester
Journal:  Antiviral Res       Date:  2015-05-12       Impact factor: 5.970

3.  Passive protection across subgroups of alphaviruses by hyperimmune non-cross-neutralizing anti-Sindbis serum.

Authors:  C J Wust; R Crombie; A Brown
Journal:  Proc Soc Exp Biol Med       Date:  1987-01

Review 4.  Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Authors:  Richard J Kuhn; Kimberly A Dowd; Carol Beth Post; Theodore C Pierson
Journal:  Virology       Date:  2015-03-30       Impact factor: 3.616

5.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

6.  Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.

Authors:  Jason Porta; Vidya Mangala Prasad; Cheng-I Wang; Wataru Akahata; Lisa F P Ng; Michael G Rossmann
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

7.  Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Authors:  Feng Long; Rachel H Fong; Stephen K Austin; Zhenguo Chen; Thomas Klose; Andrei Fokine; Yue Liu; Jason Porta; Gopal Sapparapu; Wataru Akahata; Benjamin J Doranz; James E Crowe; Michael S Diamond; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-26       Impact factor: 11.205

8.  Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.

Authors:  Chia Yin Lee; Yiu-Wing Kam; Jan Fric; Benoit Malleret; Esther G L Koh; Celine Prakash; Wen Huang; Wendy W L Lee; Cui Lin; Raymond T P Lin; Laurent Renia; Cheng-I Wang; Lisa F P Ng; Lucile Warter
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

9.  Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses.

Authors:  James Weger-Lucarelli; Matthew T Aliota; Attapon Kamlangdee; Jorge E Osorio
Journal:  PLoS Negl Trop Dis       Date:  2015-10-16

10.  Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.

Authors:  Kimberly A Dowd; Christina R DeMaso; Theodore C Pierson
Journal:  MBio       Date:  2015-11-03       Impact factor: 7.867
View more
  9 in total

Review 1.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

Review 2.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 3.  Prophylactic strategies to control chikungunya virus infection.

Authors:  Friederike I L Hucke; Malena Bestehorn-Willmann; Joachim J Bugert
Journal:  Virus Genes       Date:  2021-02-15       Impact factor: 2.332

Review 4.  Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.

Authors:  Rajesh Kumar; Tripti Shrivastava; Sweety Samal; Shubbir Ahmed; Hilal Ahmad Parray
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-19       Impact factor: 4.813

5.  Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody.

Authors:  Jinny L Liu; Emily M Webb; Dan Zabetakis; Crystal W Burke; Christina L Gardner; Pamela J Glass; Patricia M Legler; James Weger-Lucarelli; George P Anderson; Ellen R Goldman
Journal:  Front Med (Lausanne)       Date:  2021-01-28

6.  Cooperative Chikungunya Virus Membrane Fusion and Its Substoichiometric Inhibition by CHK-152 Antibody.

Authors:  Jelle S Blijleven; Ellen M Bouma; Mareike K S van Duijl-Richter; Jolanda M Smit; Antoine M van Oijen
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

7.  A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.

Authors:  Allison August; Husain Z Attarwala; Sunny Himansu; Shiva Kalidindi; Sophia Lu; Rolando Pajon; Shu Han; Jean-Michel Lecerf; Joanne E Tomassini; Marjie Hard; Leon M Ptaszek; James E Crowe; Tal Zaks
Journal:  Nat Med       Date:  2021-12-09       Impact factor: 53.440

8.  Expression, Purification, and Refolding of Chikungunya Virus Full-Length Envelope E2 Protein along with B-Cell and T-Cell Epitope Analyses Using Immuno-Informatics Approaches.

Authors:  Manisha Shukla; Pankaj Chandley; Suman Tapryal; Narendra Kumar; Sulakshana P Mukherjee; Soma Rohatgi
Journal:  ACS Omega       Date:  2022-01-14

Review 9.  Cellular and Molecular Immune Response to Chikungunya Virus Infection.

Authors:  Ithallo S B Tanabe; Eloiza L L Tanabe; Elane C Santos; Wanessa V Martins; Isadora M T C Araújo; Maria C A Cavalcante; Ana R V Lima; Niels O S Câmara; Leticia Anderson; Dinar Yunusov; Ênio J Bassi
Journal:  Front Cell Infect Microbiol       Date:  2018-10-10       Impact factor: 5.293
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.